Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 06 November 2023 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2023 of DKK 30 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 4.1 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”).
The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. B shares of DKK 0.10 will be repurchased during the trading period starting 7 November 2023 and ending on 29 January 2024. A maximum of 350,000,000 B shares of DKK 0.10 in total can be bought during the trading period.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 61,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Instagram, X, LinkedIn andYouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Elizabeth DeLuca (US) +1 609 580 9868 edel@novonordisk.com |
| Investors: | |
| Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com | Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com | Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
Company announcement No 72 / 2023
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Hexagon Purus awarded purchase order by Ford Trucks to deliver a hydrogen fuel storage system for their prototype heavy-duty truck7.12.2023 08:07:00 CET | Press release
(Oslo, 7 December 2023) Hexagon Purus, a world leading supplier of zero-emission infrastructure and mobility solutions, has been awarded a purchase order by Ford Trucks to deliver a complete hydrogen fuel storage system for development of a Fuel Cell Electric-Powered Vehicle (FCEV) F-MAX as part of the Horizon Europe project ZEFES (Zero Emission Freight EcoSystem), a zero-emission logistics deployment project in which Ford Trucks participates with the vision of pioneering future transportation solutions. As a partner in project ZEFES, a pan-European project specifically targeting decarbonization of long-haul heavy-duty trucking in Europe, Ford Trucks will develop and deliver a fuel cell electric heavy-duty prototype F-MAX truck that will operate as part of a larger fleet of zero-emission trucks collecting data from real-world operations. The F-MAX FCEV will be Ford Trucks’ first fuel cell-powered vehicle, developed and manufactured in Turkey, and will begin European Ten-T corridor demo
AB Akola Group: notification on disposal of voting rights7.12.2023 08:04:58 CET | Press release
AB Akola Group (former AB Linas Agro Group), ISIN code LT0000128092 (hereinafter - the Company), received notification from UAB „SB Asset Management“ on the disposal of voting rights due to the increase in the authorized capital of the Company (enclosed). Additional information: Mažvydas Šileika, CFO of AB Akola Group Mob. +370 619 19 403 E-mail m.sileika@akolagroup.lt Attachment Notification-of-disposal-of-block-of-shares LNA 2023 12 06-s1206
Dividend Declaration7.12.2023 08:00:00 CET | Press release
Volta Finance Limited (VTA/VTAS) Dividend Declaration NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Guernsey, 7 December 2023 Volta Finance Limited ("the Company") hereby announces that it has declared a quarterly interim dividend of €0.135 per share payable on 25 January 2024 amounting to approximately €4.94 million, approximately equating to an annualised 8.25% of net asset value. The ex-dividend date is 21 December 2023 with a record date of 22 December 2023. The Company has arranged for its shareholders to be able to elect to receive their dividends in either Euros or Pounds Sterling. Shareholders will, by default, receive their dividends in Euros, unless they have instructed the Company’s Registrar, Computershare Investor Services (Guernsey) Limited (“Computershare”), to pay dividends in Pounds Sterling. Such instructions may be given to Computershare either electronically via CREST or by using the Currency Election Form which has
Tag Systems and Fingerprint Cards AB (Fingerprints™) to bring biometric card to market7.12.2023 08:00:00 CET | Press release
Global card manufacturer Tag Systems (part of AUSTRIACARD Holdings AG) has achieved Mastercard certification for its biometric card based on Fingerprint Cards’ sensor and STMicroelectronics STPay-Topaz-Bio solution. Banks and fintechs can now issue Mastercard-branded biometric payment cards to enhance convenience and security for cardholders. Roger Carrico, Vice President, Head of Sales & Business development, Payment & Access at Fingerprints comments: “In Tag Systems we have a partner that likes to lead the way with high-end payment services. Banks and fintechs can take advantage of the opportunity to differentiate, retain and acquire customers and drive revenues.” Jon Neeraas, CEO at Tag Systems adds: “With this certification, we are excited to support our partners in issuing top-of-wallet biometric cards that utilize Fingerprints and ST latest technologies. Together, we are creating convenient, hygienic, and secure transactions for all purchases.” Following a partnership agreement i
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial7.12.2023 08:00:00 CET | Press release
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the understanding and treatment of urea associated skin diseases that has puzzled scientists for decadesMC2-25 CKD uses a di-peptide as an iso-cyanate scavenger to inhibit carbamylation of amino acids and proteins in the skinMC2-25 CKD has the potential to become the world’s first approved treatment for pre-dialysis Chronic Kidney Disease-associated Pruritus (CKD-aP), a debilitating condition thought to affect a significant proportion of the ~800 million people globally who suffer from Chronic Kidney Disease (CKD)111 patients enrolled in the multi-center trial across Europe with topline results expected in Q2 2024 Copenhagen, December 7th, 2023 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory conditions,